226 related articles for article (PubMed ID: 34408553)
21. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
22. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
23. BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.
Hwang KT; Kim K; Chang JH; Oh S; Kim YA; Lee JY; Jung SH; Choi IS
Cancer Res Treat; 2018 Jul; 50(3):658-669. PubMed ID: 28701032
[TBL] [Abstract][Full Text] [Related]
24. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
[TBL] [Abstract][Full Text] [Related]
25. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
26. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.
Xiao B; Zhang W; Chen L; Hang J; Wang L; Zhang R; Liao Y; Chen J; Ma Q; Sun Z; Li L
Gene; 2018 Jun; 658():28-35. PubMed ID: 29518546
[TBL] [Abstract][Full Text] [Related]
28. Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer.
Wang L; Xiao Y; Ping Y; Li J; Zhao H; Li F; Hu J; Zhang H; Deng Y; Tian J; Li X
PLoS One; 2014; 9(8):e104282. PubMed ID: 25137136
[TBL] [Abstract][Full Text] [Related]
29. Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
Zhao Q; Song W; He DY; Li Y
Breast Cancer; 2018 Mar; 25(2):213-223. PubMed ID: 29170883
[TBL] [Abstract][Full Text] [Related]
30. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.
Wolf DM; Lenburg ME; Yau C; Boudreau A; van 't Veer LJ
PLoS One; 2014; 9(2):e88309. PubMed ID: 24516633
[TBL] [Abstract][Full Text] [Related]
31. Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes.
Han B; Zhang H; Zhu Y; Han X; Wang Z; Gao Z; Yuan Y; Tian R; Zhang F; Niu R
Aging (Albany NY); 2020 Jul; 12(13):13318-13337. PubMed ID: 32649310
[TBL] [Abstract][Full Text] [Related]
32. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract][Full Text] [Related]
33. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
34. [Data mining of esophageal squamous cell carcinoma from The Cancer Genome Atlas database].
He SY; Wang XB; Jiao YC
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):517-522. PubMed ID: 30060360
[No Abstract] [Full Text] [Related]
35. Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell Genotypes and Stroke Risk in Breast Cancer Microenvironment.
Wu JY; Qin J; Li L; Zhang KD; Chen YS; Li Y; Jin T; Xu JM
Oxid Med Cell Longev; 2021; 2021():5633514. PubMed ID: 34457116
[TBL] [Abstract][Full Text] [Related]
36. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
37. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
[TBL] [Abstract][Full Text] [Related]
38. Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer.
Li Y; Yang X; Geng C; Liu Y; Tang T; Zhang L; Liu F; Zhang M; Hao J; Ma L
Front Immunol; 2024; 15():1390261. PubMed ID: 38726001
[TBL] [Abstract][Full Text] [Related]
39. Identification of Hub Genes Using Co-Expression Network Analysis in Breast Cancer as a Tool to Predict Different Stages.
Fu Y; Zhou QZ; Zhang XL; Wang ZZ; Wang P
Med Sci Monit; 2019 Nov; 25():8873-8890. PubMed ID: 31758680
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the aberrantly expressed lncRNA‑associated ceRNA network in breast cancer.
Tuersong T; Li L; Abulaiti Z; Feng S
Mol Med Rep; 2019 Jun; 19(6):4697-4710. PubMed ID: 31059025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
